Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
2/2019 ceased to operate
CureTech
CureTech Overview
CureTech is a biotechnology company developing broad-spectrum, immune-modulating products for the treatment and control of cancer. Its product line includes antibodies and peptide-based vaccines designed to modulate the immune response, allowing it to exert its anti-cancer activity in an effective manner. CureTech's lead humanized antibody product, pidilizumab (CT-011), is in Phase II clinical testing. Pidilizumab has shown promising results in attenuating tumor growth and eliminating tumor metastases in a variety of model systems. Several patents and pending patent applications worldwide protect the company's products. A licensing agreement for further development and commercialization of pidilizumab was signed with Medivation in 2014. In 2018, InSight Innovations acquired CureTech.
Cumulative Funding Raised Over Time ($)
Employees Over Time
CureTech Climate Tech relevance
undefined
Latest News
No Data, yet.
Sorry, no content found under this section.
Feb 3, 2020
www.calcalistech.com
CureTech's Cancer-Fighting Dreams End With Insolvency
#Investment #Acquisition #Layoffs
Jul 5, 2018
www.calcalistech.com
Cost-Cutting at CureTech Following Cancellation of Acquisition Deal with Insight
#Acquisition
Mar 28, 2018
www.globes.co.il
InSight Innovations buys CureTech for up to $550m
#Acquisition
Oct 1, 2017
www.globes.co.il
CureTech buys back cancer drug from Pfizer for $20m
#Acquisition #Layoffs
Dec 21, 2014
www.globes.co.il
Medivation takes up $335m Curetech licensing option